Pfizer und BioNTech geben erste positive Daten für mRNA-basiertes Kombinationsimpfstoffprogramm gegen Influenza und COVID-19 bekannt
October 26, 2023 06:45 ET
|
BioNTech SE
Die in der Phase-1/2-Studie untersuchten führenden Kombi-Impfstoffformulierungen zeigten robuste Immunantworten gegen Influenza A, Influenza B und SARS-CoV-2-Stämme Das Sicherheitsprofil der...
Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
October 25, 2023 16:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases
October 05, 2023 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Pneumagen Announces Successful Clinical Proof of Concept for its Broad-Spectrum Antiviral Neumifil in Phase 2 Influenza Human Challenge Study
October 02, 2023 04:00 ET
|
Pneumagen Ltd
Study achieves primary & secondary endpoints in a randomised, placebo-controlled challenge studyNeumifil delivers a statistically significant reduction in both symptomatic infection rate &...
Dyadic to Present at Industry and Investor Events in October
September 29, 2023 08:30 ET
|
Dyadic International, Inc.
Dyadic to Present at Industry and Investor Events in October
Infectious Disease Diagnostics Market to Hit $37.94 Billion, Globally, by 2028 – Exclusive Report by The Insight Partners
September 20, 2023 10:22 ET
|
The Insight Partners
Pune, India., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Tuberculosis (TB) is the 13th most significant cause of mortality globally and the second leading infectious disease after COVID-19, according to the...
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness
July 20, 2023 08:00 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, July 20, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR-2482...
LEX Diagnostics Appoints Chief Technology Officer
July 18, 2023 03:00 ET
|
LEX Diagnostics
CAMBRIDGE, United Kingdom, July 18, 2023 (GLOBE NEWSWIRE) -- LEX Diagnostics (LEX) today announces the appointment of Dr Heather Danks as its Chief Technology Officer (CTO). The company is...
Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity
June 21, 2023 08:33 ET
|
Dyadic International, Inc.
JUPITER, Fla. and DHAKA, Bangladesh, June 21, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company...
Influenza Vaccines Market Size to Surpass USD 11.7 Billion by 2030 at 6.53% CAGR – Report by Market Research Future (MRFR)
May 29, 2023 09:30 ET
|
Market Research Future
New York, USA, May 29, 2023 (GLOBE NEWSWIRE) -- Influenza Vaccines Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “Influenza Vaccines Market...